Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please ...

Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.

Recent studies highlight the potential of minimal residual disease (MRD) testing to influence treatment decisions in multiple myeloma and chronic lymphocytic leukemia. Testing for minimal residual ...

Coverage marks a pivotal step in expanding access to ultra-sensitive MRD detection for breast cancer patients U.S. Medicare coverage decision reflects published, peer-reviewed clinical data ...

(RTTNews) - Myriad Genetics, Inc. (MYGN) announced new interim data from the MONSTAR-SCREEN-3 study, showcasing the high sensitivity and pan-cancer applicability of its Precise Minimal Residual ...

MRD signifies remaining cancer cells post-treatment, with interpretations varying by cancer type. MRD testing methods include flow cytometry and genomic tests, detecting residual cancer cells.

MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...

clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial ...

Quest Diagnostics can benefit from continued demand for specific diagnostic testing across a broad range of clinical areas.

An innovative approach could transform the treatment landscape for DLBCL patients, offering hope to those who might otherwise ...

A looming revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster biotech stocks like Guardant Health, Natera and Exact Sciences. And all it takes is a little blood.